Compounders Research Compare

Shattuck Labs, Inc.(STTK)

Biotechnology · Austin, TX

$5.86-0.64 (-9.85%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Shattuck Labs, Inc.

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

Austin, TX

40 employees

www.shattucklabs.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Taylor H. Schreiber

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T20:04:30.817Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:04:30.817Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 529,582,205
Total debt · period ending 2026-06-30: 2,674,000
Cash · period ending 2026-06-30: 63,299,000
TTM operating income · period ending 2026-06-30: -55,787,000

FMP input reference: 35a271d61501d442ff1d5238fcf80e89d6bdfa5e87b371fe53e06a7cba571f48

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

STTK EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

STTK Competitors' EV/EBIT Ratio

Shattuck Labs, Inc.

Current

Market Cap

$529.58M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nuvectis Pharma, Inc.

Market Cap

$531.52M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Delcath Systems, Inc.

Market Cap

$531.98M

EV/EBIT Ratio

N/A

TTM Avg

189.50x

3Y Avg

189.50x

5Y Avg

189.50x

Monopar Therapeutics Inc.

Market Cap

$533.04M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immix Biopharma, Inc.

Market Cap

$524.43M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ProKidney Corp.

Market Cap

$538.01M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Altimmune, Inc.

Market Cap

$519.25M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aclaris Therapeutics, Inc.

Market Cap

$516.76M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Phathom Pharmaceuticals, Inc.

Market Cap

$548.51M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

908 Devices Inc.

Market Cap

$505.87M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Shattuck Labs, Inc. (STTK)	$529.58M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$531.52M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$531.98M	N/A	189.50x	189.50x	189.50x
Monopar Therapeutics Inc. (MNPR)vs ›	$533.04M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$524.43M	N/A	N/A	N/A	N/A
ProKidney Corp. (PROK)vs ›	$538.01M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$519.25M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$516.76M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$548.51M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$505.87M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics